Action Vir Biotechnology - VIR

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Dernier

9,85

Prix Achat

9,68

Prix Vente

10,00

Volume échangé

655 687

9,60 Fourchette du Jour 9,9664

6,56 Plage de 52 semaines 14,43

Cap du marché

1,357B

Clôture Veille

9,685

Ouverture

9,60

Dernière Transaction

208

9.85

(priorref)

Dernière heure de transaction

Volume financier

US$ 6 437 530

VWAP

9,818

Volume moyen (3 m)

2 211 013

Actions en circulation

137 720 120

Rendement du Dividende

Ratio Cours sur Bénéfices

-2,21

Bénéfice par action (BPA)

-4,47

Chiffre d'affairess

86,18M

Bénéfice net

-615,06M

Vir Biotechnology Inc is a commercial-stage immunology company focused on treating and preventing infectious diseases. It has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA, through internal development, collaborations, an... Vir Biotechnology Inc is a commercial-stage immunology company focused on treating and preventing infectious diseases. It has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA, through internal development, collaborations, and acquisitions. The company's pipeline consists of product candidates targeting hepatitis B virus, or HBV, influenza A, human immunodeficiency virus, or HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue and license revenue. Show more

Secteur

Biological Pds,ex Diagnstics

Industrie

Biological Pds,ex Diagnstics

Site Web

www.vir.bio

Siège social

Wilmington, Delaware, USA

Fondé

Vir Biotechnology Inc est coté dans le secteur Biological Pds,ex Diagnstics de la NASDAQ avec le ticker VIR. Le dernier cours de clôture d'Vir Biotechnology était de US$9,69. Au cours de la dernière année, les actions de Vir Biotechnology ont été négociées dans une fourchette de prix de US$ 6,56 à US$ 14,43.

Vir Biotechnology compte actuellement 137 720 120 actions en circulation. La capitalisation boursière d'Vir Biotechnology est de US$1,33 milliard. Vir Biotechnology a un ratio cours/bénéfice (ratio PE) de -2.21.

Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that members of the executive team are scheduled to participate in a fireside chat at the...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that the Company will provide a corporate update and report financial results for the...

Form 8-K - Current report

Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC

– Compelling early clinical response signals for VIR-5818 and VIR-5500 in heavily pretreated patients with various solid tumors ○ VIR-5818: In...

Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Vir Biotechnology Inc. (NASDAQ: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the...

Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta

– Designations aim to expedite the development and review of promising therapies for serious conditions with unmet medical needs – – Phase 3...

Form 4 - Statement of changes in beneficial ownership of securities

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0.97	10.9234234234	8.88	10.01	8.84	966075	9.50102384	CS
4	-0.55	-5.28846153846	10.4	11.26	8.84	1291249	10.01998903	CS
12	2.22	29.0956749672	7.63	14.43	7.025	2211013	10.34334903	CS
26	1.25	14.5348837209	8.6	14.43	6.56	1505656	9.49908046	CS
52	-0.36	-3.52595494613	10.21	14.43	6.56	1279915	9.66206606	CS
156	-19.65	-66.6101694915	29.5	31.78	6.56	1206499	16.17983262	CS
260	-7.77	-44.0976163451	17.62	141.01	6.56	1222162	27.20122625	CS

VIR - Frequently Asked Questions (FAQ)

What is the current Vir Biotechnology share price?

The current share price of Vir Biotechnology is US$ 9,85

How many Vir Biotechnology shares are in issue?

Vir Biotechnology has 137 720 120 shares in issue

What is the market cap of Vir Biotechnology?

The market capitalisation of Vir Biotechnology is USD 1,33B

What is the 1 year trading range for Vir Biotechnology share price?

Vir Biotechnology has traded in the range of US$ 6,56 to US$ 14,43 during the past year

What is the PE ratio of Vir Biotechnology?

The price to earnings ratio of Vir Biotechnology is -2,21

What is the cash to sales ratio of Vir Biotechnology?

The cash to sales ratio of Vir Biotechnology is 15,74

What is the reporting currency for Vir Biotechnology?

Vir Biotechnology reports financial results in USD

What is the latest annual turnover for Vir Biotechnology?

The latest annual turnover of Vir Biotechnology is USD 86,18M

What is the latest annual profit for Vir Biotechnology?

The latest annual profit of Vir Biotechnology is USD -615,06M

What is the registered address of Vir Biotechnology?

The registered address for Vir Biotechnology is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808

What is the Vir Biotechnology website address?

The website address for Vir Biotechnology is www.vir.bio

Which industry sector does Vir Biotechnology operate in?

Vir Biotechnology operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
JTAIJet AI Inc	US$ 10,1006 (148,78%)	149,38M
EDITEditas Medicine Inc	US$ 3,19 (83,33%)	49,89M
SINTSiNtx Technologies Inc	US$ 4,79 (69,86%)	70,97M
LYTLytus Technologies Holdings PTV Ltd	US$ 0,363 (63,07%)	215,48M
AGHAureus Greenway Holdings Inc	US$ 3,8501 (42,07%)	1,02M
CNSPCNS Pharmaceuticals Inc	US$ 0,0838 (-41,19%)	88,17M
HCTIHealthcare Triangle Inc	US$ 0,4409 (-38,76%)	3,19M
NKLANikola Corporation	US$ 0,4711 (-38,49%)	110,5M
BPTHBio Path Holdings Inc	US$ 0,1322 (-37,05%)	2,14M
GLSTUGlobal Star Acquisition Inc	US$ 7,26 (-36,04%)	4,41k
ADTXAditxt Inc	US$ 0,1288 (17,09%)	612,1M
BHATBlue Hat Interactive Entertainment Technology	US$ 0,0616 (13,03%)	482,51M
SMCISuper Micro Computer Inc	US$ 60,25 (7,97%)	338,03M
LYTLytus Technologies Holdings PTV Ltd	US$ 0,363 (63,07%)	215,48M
NVDANVIDIA Corporation	US$ 139,23 (-0,12%)	168,02M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Vir Biotechnology Inc (VIR) Cours

Vir Biotechnology Inc (VIR)

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

À propos de Vir Biotechnology Inc

VIR Dernières nouvelles

Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

Form 8-K - Current report

Form 8-K - Current report

Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC

Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta

Form 4 - Statement of changes in beneficial ownership of securities

Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

Form 8-K - Current report

Form 8-K - Current report

Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC

Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs

VIR - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités